BIOARTIFICIAL LIVER SUPPORT OF SPLIT LIVER

描述（改编自研究者摘要）：原位肝脏 肝移植（OLTx）是治疗肝衰竭的唯一有效方法。 不幸的是，对肝脏的需求远远超过了供应。部分肝 来自活体、亲属或其他捐赠者的移植提供了弥合 供需之间的差距。然而，这种移植使捐赠者在 肝衰竭或其他相关疾病的风险。 此外，移植的部分移植物占不到30%， 正常肝脏大小的移植通常会失败。由于这些原因，生活 供体OLTx并不常见。明确需要一种技术， 在移植患者中存在大部分肝移植物存活。等 技术将允许使用较小的供体移植物，这一特征也将 降低与移植物捐献相关的发病率。该提案测试了 生物人工肝系统可用于提供肝脏的假设 在关键的3-5天后，为接受次优肝移植的猪提供支持 移植期猪的存活率的提高 生物人工肝可以考虑用于提供肝脏支持 对于部分肝OLTx或根治性（80%）肝切除术的患者 用于治疗转移性癌症 拟定商业应用： 临床上有效的生物人工肝系统将在多种领域中应用。 患者出现重度肝功能不全的临床情况，包括 急性肝衰竭，慢性肝病急性失代偿，临时支持 供体和/或受体在活体相关肝脏捐赠和积极切除 有病的肝脏

DESCRIPTION (Adapted from the Investigator's Abstract): Orthotopic liver transplantation (OLTx) is the only effective treatment for liver failure. Unfortunately, the demand for livers greatly exceeds the supply. Partial liver transplants from living, related or other donors offer the potential to bridge the gap between need and supply. However, such transplants put the donor at risk with regard to liver failure or other associated morbidities. Additionally, transplanted partial grafts that represent less than 30 percent of normal liver size in the recipient generally fail. For these reasons, living donor OLTx is not common. A clear need for a technology that can help minimally sized partial liver grafts survive in transplanted patient exists. Such technology will permit use of smaller donor grafts, a feature that will also reduce the morbidity associated with graft donation. This proposal tests the hypothesis that a bioartificial liver system can be used to provide liver support to pigs with sub-optimal liver grafts for the critical 3-5 day post transplant period. An increased survival rate of the pigs would be evidence that the bioartificial liver could be considered for provision of liver support for patients with partial live OLTx or radical (80 percent) liver resections for treatment of metastatic cancer. PROPOSED COMMERCIAL APPLICATION: A clinically effective bioartificial liver system would have applications in a variety of clinical situations where a patient experiences severe hepatic insufficiency including acute liver failure, acute de-compensation on chronic liver disease, temporary support of donors and/or recipients in living related liver donation and aggressive resections of diseased livers.